MA32059B1 - Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique - Google Patents

Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Info

Publication number
MA32059B1
MA32059B1 MA33057A MA33057A MA32059B1 MA 32059 B1 MA32059 B1 MA 32059B1 MA 33057 A MA33057 A MA 33057A MA 33057 A MA33057 A MA 33057A MA 32059 B1 MA32059 B1 MA 32059B1
Authority
MA
Morocco
Prior art keywords
group
heterocyclic
alkyl
hydrogen atom
imidazo
Prior art date
Application number
MA33057A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-François Peyronel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32059(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32059B1 publication Critical patent/MA32059B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule (i) dans laquelle : x représente un groupe hétérocyclique; r1 représente un atome d'hydrogène, un atome d'halogène, un groupe (c1-c6)alcoxy, un groupe (c2-c6)alkyle), un groupe nrarb; r2 représente un atome d'hydrogène, un groupe (c1-c6)alkyle éventuellement substitué, un groupe (c1-c6)alcoxy éventuellement substitué, un groupe (c2-c6)alcényle, un groupe (c2-c6)alcynyle, un groupe -co-r5, un groupe -co-nr6r7,un groupe -co-o-r8, un groupe -nr9-co-r10, un groupe -nr11r12, un groupe -n=ch-nrarb, un atome d'halogène, un groupe cyano, nitro, hydroxyiminoalkyle, alcoxyiminoalkyle, un groupe (c1-c6)alkylthio, un groupe (c1-c6)alkylsulfinyle, un groupe (c1-c6)alkylsulfonyle, un groupe ((c1 c6)alkyl)3)silyléthynyle, un groupe -so2-nr9r10, un groupe phényle éventuellement substitué; r3 représente un atome d'hydrogène, un groupe (c2-c6)alkyle un groupe (c1-c6)alcoxy ou un atome d'halogène; r4 représente un atome d'hydrogène, un groupe (c1-c4)alkyle, un groupe (c1-c4)alcoxy ou un atome de fluor, à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique.
MA33057A 2008-01-02 2010-08-02 Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique MA32059B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800003A FR2925901B1 (fr) 2008-01-02 2008-01-02 DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
PCT/FR2008/001834 WO2009106749A2 (fr) 2008-01-02 2008-12-31 Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MA32059B1 true MA32059B1 (fr) 2011-02-01

Family

ID=39712153

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33057A MA32059B1 (fr) 2008-01-02 2010-08-02 Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Country Status (20)

Country Link
US (1) US20100317673A1 (fr)
EP (1) EP2225242A2 (fr)
JP (1) JP2011509250A (fr)
KR (1) KR20100099244A (fr)
CN (1) CN101910172A (fr)
AR (1) AR070072A1 (fr)
AU (1) AU2008351927A1 (fr)
BR (1) BRPI0821992A2 (fr)
CA (1) CA2710860A1 (fr)
CL (1) CL2008003933A1 (fr)
CO (1) CO6331306A2 (fr)
EA (1) EA201070813A1 (fr)
FR (1) FR2925901B1 (fr)
IL (1) IL206671A0 (fr)
MA (1) MA32059B1 (fr)
MX (1) MX2010007349A (fr)
TW (1) TW200934777A (fr)
UY (2) UY3816Q (fr)
WO (1) WO2009106749A2 (fr)
ZA (1) ZA201004643B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
JP5868996B2 (ja) 2010-12-13 2016-02-24 アレイ バイオファーマ、インコーポレイテッド ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物
WO2012147890A1 (fr) * 2011-04-27 2012-11-01 持田製薬株式会社 Nouveau dérivé d'azole
WO2014103801A1 (fr) * 2012-12-28 2014-07-03 株式会社新日本科学 Inhibiteur de l'activité d'oct3 contenant un dérivé d'imidazopyridine en tant que principe actif, et agent de détection d'oct3
EP3946618A1 (fr) * 2019-04-05 2022-02-09 Storm Therapeutics Ltd Composés inhibiteurs de mettl3
WO2022074379A1 (fr) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3
EP4596548A1 (fr) * 2024-02-05 2025-08-06 Ludwig-Maximilians-Universität Modulateurs de nurr1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja) * 2007-02-06 2013-12-04 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
IL206671A0 (en) 2010-12-30
ZA201004643B (en) 2011-09-28
AU2008351927A1 (en) 2009-09-03
CO6331306A2 (es) 2011-10-20
CA2710860A1 (fr) 2009-09-03
EP2225242A2 (fr) 2010-09-08
FR2925901A1 (fr) 2009-07-03
CL2008003933A1 (es) 2010-02-12
FR2925901B1 (fr) 2011-03-04
WO2009106749A3 (fr) 2010-05-06
EA201070813A1 (ru) 2010-12-30
UY31587A1 (es) 2009-08-03
JP2011509250A (ja) 2011-03-24
KR20100099244A (ko) 2010-09-10
TW200934777A (en) 2009-08-16
UY3816Q (es) 2008-09-30
AR070072A1 (es) 2010-03-10
BRPI0821992A2 (pt) 2015-06-23
US20100317673A1 (en) 2010-12-16
WO2009106749A2 (fr) 2009-09-03
MX2010007349A (es) 2010-08-18
CN101910172A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
MA32059B1 (fr) Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
RU2502730C2 (ru) Сульфонамидные соединения и их применение
MA32057B1 (fr) Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique
MA32248B1 (fr) Dérivés polysubstitues de 6-heteroaryle-imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
WO2005080384A3 (fr) Dérivé du benzimidazole et ses utilisations
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
WO2009156861A3 (fr) Dérivés de pyrimidone substitués
GEP201706728B (en) Noxious organism control agent
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
PE20110568A1 (es) Agentes terapeuticos 414
MY168283A (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
MA32036B1 (fr) Composés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
MXPA05013856A (es) Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MA32527B1 (fr) Derives 6-heterocyclique -imidazo[1,2-a]pyrroine-2-carboxamides, leur preparation et leur application en therapeutique
EA201000604A1 (ru) Новые производные имидазола
WO2008003858A3 (fr) Utilisation de dérivés d'imidazo[1, 2-a]pyridine-2-carboxamides en thérapeutique
MA32058B1 (fr) Dérivés de n-heterocyclique-6-heterocyclique-imidazo [1, 2-a] pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
MA32060B1 (fr) Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
RU2008152764A (ru) Биарилкарбоксиариламиды как модуляторы ванилоидного рецептора типа 1
EA200700179A1 (ru) Производные пиррола, их получение и их применение в терапии
TNSN07373A1 (fr) 7-fluoro-1,3-dihydro-indole-2-one-oxazolidinones servant d'agents antibacteriens
MA32053B1 (fr) Nouveaux composes piperidiniques , leur procede de preparation et les compositions pharmaceutiques qui les contiennent